Drug-induced liver injury associated with savolitinib: a novel case report and causality assessment.
Case report
Hepatic failure
Non-small cell Lung Cancer
Savolitinib
Targeted therapy
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
09 Aug 2024
09 Aug 2024
Historique:
received:
12
03
2024
accepted:
07
08
2024
medline:
10
8
2024
pubmed:
10
8
2024
entrez:
9
8
2024
Statut:
epublish
Résumé
Savolitinib, a small molecule inhibitor, has gained approval as the inaugural medication in China that specifically targets MET kinase. Patients with advanced non-small cell lung cancer (NSCLC) who show MET exon 14 skipping now have a new and innovative treatment option available. In this case report, we describe a patient who experienced drug-induced liver injury (DILI) due to the administration of savolitinib. After being prescribed with savolitinib (400 mg per day, oral), a 73-year-old male diagnosed with stage IV NSCLC with MET exon 14 skipping mutation experienced an increase in liver enzymes and bilirubin levels according to his laboratory tests conducted one month later. Following a 14-day course of hepatoprotective medication, the liver function reverted back to its normal state. After receiving savolitinib (200 mg per day, oral) for one week, the patient was once again diagnosed with severe liver impairment. Then savolitinib was discontinued and received treatment with hepatoprotective drugs for one week. Following the restoration of normal liver function, another attempt was made to administer a small amount of savolitinib (100 mg per day, oral). Thus far, the patient has been followed up and there has been no recurrence of liver damage. Additionally, the lung CT scan revealed ongoing tumor shrinkage with no apparent indications of spreading or metastasis. The Roussel Uclaf Causality Assessment Method (RUCAM) determined that savolitinib was "highly probable" cause of DILI. Moderate-severe was determined to be the extent of DILI severity. To the best of our understanding, this is the initial instance of DILI resulting from the use of savolitinib as a standalone treatment in a real-world setting. During the administration of savolitinib, healthcare professionals should carefully consider the potential occurrence of DILI. Administering the patient with a small amount of savolitinib resulted in a remarkable response against the tumor, leading us to speculate that the effectiveness of savolitinib might be associated with its plasma concentration. Studying the pharmacokinetics and pharmacodynamics (PK/PD) of savolitinib is beneficial for tailoring and accurately prescribing the medication to each individual.
Sections du résumé
BACKGROUND
BACKGROUND
Savolitinib, a small molecule inhibitor, has gained approval as the inaugural medication in China that specifically targets MET kinase. Patients with advanced non-small cell lung cancer (NSCLC) who show MET exon 14 skipping now have a new and innovative treatment option available.
CASE REPORT
METHODS
In this case report, we describe a patient who experienced drug-induced liver injury (DILI) due to the administration of savolitinib. After being prescribed with savolitinib (400 mg per day, oral), a 73-year-old male diagnosed with stage IV NSCLC with MET exon 14 skipping mutation experienced an increase in liver enzymes and bilirubin levels according to his laboratory tests conducted one month later. Following a 14-day course of hepatoprotective medication, the liver function reverted back to its normal state. After receiving savolitinib (200 mg per day, oral) for one week, the patient was once again diagnosed with severe liver impairment. Then savolitinib was discontinued and received treatment with hepatoprotective drugs for one week. Following the restoration of normal liver function, another attempt was made to administer a small amount of savolitinib (100 mg per day, oral). Thus far, the patient has been followed up and there has been no recurrence of liver damage. Additionally, the lung CT scan revealed ongoing tumor shrinkage with no apparent indications of spreading or metastasis. The Roussel Uclaf Causality Assessment Method (RUCAM) determined that savolitinib was "highly probable" cause of DILI. Moderate-severe was determined to be the extent of DILI severity.
CONCLUSION
CONCLUSIONS
To the best of our understanding, this is the initial instance of DILI resulting from the use of savolitinib as a standalone treatment in a real-world setting. During the administration of savolitinib, healthcare professionals should carefully consider the potential occurrence of DILI. Administering the patient with a small amount of savolitinib resulted in a remarkable response against the tumor, leading us to speculate that the effectiveness of savolitinib might be associated with its plasma concentration. Studying the pharmacokinetics and pharmacodynamics (PK/PD) of savolitinib is beneficial for tailoring and accurately prescribing the medication to each individual.
Identifiants
pubmed: 39123181
doi: 10.1186/s12890-024-03201-8
pii: 10.1186/s12890-024-03201-8
doi:
Substances chimiques
Acrylamides
0
Protein Kinase Inhibitors
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
384Subventions
Organisme : Fundamental Research Funds for the Central Universities
ID : 24X010301395
Informations de copyright
© 2024. The Author(s).
Références
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
doi: 10.3322/caac.21492
pubmed: 30207593
Ma PC, Kijima T, Maulik G, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003;63(19):6272–81.
pubmed: 14559814
Ma PC, Jagadeeswaran R, Jagadeesh S et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005 15;65(4):1479–88.
Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015;5(8):850–9.
doi: 10.1158/2159-8290.CD-15-0285
pubmed: 25971938
Schrock AB, Frampton GM, Suh J, et al. Characterization of 298 patients with Lung Cancer Harboring MET exon 14 skipping alterations. J Thorac Oncol. 2016;11(9):1493–502.
doi: 10.1016/j.jtho.2016.06.004
pubmed: 27343443
Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543–50.
doi: 10.1038/nature13385
Dhillon S, Capmatinib. First Approval Drugs. 2020;80(11):1125–31.
pubmed: 32557339
Markham A, Tepotinib. First Approval Drugs. 2020;80(8):829–33.
pubmed: 32361823
Mathieu LN, Larkins E, Akinboro O, et al. FDA approval Summary: Capmatinib and Tepotinib for the treatment of metastatic NSCLC harboring MET exon 14 skipping mutations or alterations. Clin Cancer Res. 2022;28(2):249–54.
doi: 10.1158/1078-0432.CCR-21-1566
pubmed: 34344795
Markham A, Savolitinib. First Approval Drugs. 2021;81(14):1665–70.
pubmed: 34455538
Danan G, Benichou C. Causality assessment of adverse reactions to drugs–I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46(11):1323–30.
doi: 10.1016/0895-4356(93)90101-6
pubmed: 8229110
European Association for the Study of the Liver, Andrade RJ. Clinical practice Guideline Panel members. Karlsen T.H. EASL Clinical Practice guidelines: drug-induced liver injury. J Hepatol. 2019;70(6):1222–61.
doi: 10.1016/j.jhep.2019.02.014
Yu YC, Mao YM, Chen CW, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017;11(3):221–41.
doi: 10.1007/s12072-017-9793-2
pubmed: 28405790
Prevention and Treatment Technology Professional Committee of Drug-Induced Liver Injury, China Pharmaceutical Biotechnology Association; Drug-Induced Liver Disease Group, Hepatology Branch of Chinese Medical Association. Chinese guidelines for the diagnosis and treatment of Drug-Induced Liver Injury (2023 Edition) [J]. Chin J Hepatol. 2023;31(4):355–84.
European Association for the Study of the Liver. EASL Clinical Practice guidelines on Hepatitis E virus infection. J Hepatol. 2018;68(6):1256–71.
doi: 10.1016/j.jhep.2018.03.005
Wang G, Tanaka A, Zhao H, et al. The Asian Pacific Association for the study of the liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis. Hepatol Int. 2021;15(2):223–57.
doi: 10.1007/s12072-021-10170-1
pubmed: 33942203
Crabb DW, Im GY, Szabo G, et al. Diagnosis and treatment of Alcohol-Associated Liver diseases: 2019 Practice Guidance from the American Association for the study of Liver diseases. Hepatology. 2020;71(1):306–33.
doi: 10.1002/hep.30866
pubmed: 31314133
European Association for Study of Liver. EASL Clinical Practice guidelines: Wilson’s disease. J Hepatol. 2012;56(3):671–85.
doi: 10.1016/j.jhep.2011.11.007
Miah K, Vishwanathan K, Scarfe G, et al. A phase 1 study to evaluate absolute bioavailability and absorption, distribution, metabolism, and excretion of Savolitinib in Healthy male volunteers. Clin Pharmacol Drug Dev. 2023;12(4):424–35.
doi: 10.1002/cpdd.1224
pubmed: 36808891
Pal SK, Tangen C, Thompson IM Jr, et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet. 2021;397(10275):695–703.
doi: 10.1016/S0140-6736(21)00152-5
pubmed: 33592176
pmcid: 8687736
Choueiri TK, Heng DYC, Lee JL, et al. Efficacy of Savolitinib vs Sunitinib in patients with MET-Driven papillary renal cell carcinoma: the SAVOIR phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6(8):1247–55.
doi: 10.1001/jamaoncol.2020.2218
pubmed: 32469384
Suárez C, Larkin JMG, Patel P, et al. Phase II study investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO). J Clin Oncol. 2023;41(14):2493–502.
doi: 10.1200/JCO.22.01414
pubmed: 36809050